secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-06-03T11:35:14+00:00
Accession:  0001193125-26-254597
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients
--------------------------------------------------------------------------------

- Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.
- Potential BLA submission for U.S. Accelerated Approval in Q3 2027 using REC and MAD/LTE data.
- Potential U.S. launch of z-basivarsen in H1 2028 if FDA grants Priority Review.
- Also pursuing approval pathways outside U.S. for DM1 therapy.
- ACHIEVE primary endpoint: change in middle finger myotonia via vHOT at 6 months vs placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/0001193125-26-254597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer